Breast cancer liver metastasis: time to resection and criteria

Giovinazzo, Francesco; Bucaro, Angela; Agnes, Salvatore

doi:10.21037/hbsn-22-372

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver metastasis is also one of the leading causes of death in patients with advanced breast cancer. Previous studies have found that breast cancer patients with liver metastases have a relatively poorer prognosis compared with patients with lung and bone metastases [ 17 ]. The prognosis of patients with liver metastases in this study was poor, consistent with previously reported results.…”

Section: Discussionmentioning

confidence: 99%

A real‐world study of immune checkpoint inhibitors in advanced triple‐negative breast cancer

Zhang

Liu

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

Background Triple‐negative breast cancer (TNBC) is the most aggressive type of breast cancer. Immune checkpoint inhibitors (ICIs) have been widely used to treat various tumors and have changed the landscape of tumor management, but the data from real‐world studies of ICIs for TNBC treatment remain limited. The aim of this study was to evaluate the efficacy of ICIs in the treatment of patients with advanced TNBC in a real‐world setting and to explore possible correlates. Methods The clinical data of advanced TNBC patients who received ICI treatment in the Chinese People's Liberation Army (PLA) General Hospital were collected. Treatment responses, outcomes and adverse events (AEs) were assessed. Results Eighty‐one patients were included in the study. The confirmed objective response rate (ORR) was 32.1%, and the disease control rate (DCR) was 64.2%. The median progression‐free survival (PFS) was 4.2 months, and the median overall survival (OS) was 11.0 months. PFS and OS were longer in patients who achieved clinical benefit from ICIs and shorter in patients who received later‐line ICIs and higher levels of inflammation; specifically, patients with higher TILs had longer PFS. Overall AEs were tolerable. Conclusions ICIs are effective in the treatment of advanced TNBC, and the adverse reactions are tolerable. A panel of biomarkers including LDH, ALP, and bNLR were identified to predict the efficacies of ICIs in TNBC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

A real‐world study of immune checkpoint inhibitors in advanced triple‐negative breast cancer

Zhang

Liu

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

show abstract

Outpatient and Ambulatory Extended Recovery Robotic Hepatectomy: Multinational Study of 307 Cases

Park,

Lafaro,

Hagendoorn

et al. 2024

Journal of the American College of Surgeons

View full text Add to dashboard Cite

Background: For open minor hepatectomy, morbidity and recovery are dominated by the incision. The robotic approach may transform this “incision dominant procedure” into a safe outpatient procedure. Study Design: We audited outpatient (<2 midnights) robotic hepatectomies at six hepatobiliary centers in two nations to test the hypothesis that the robotic approach can be a safe and effective short-stay procedure. ERAS programs were active at all sites, and home digital monitoring was available at one of the institutions. Results: Three hundred and seven outpatient (26 same-day, 281 next-day discharge) robotic hepatectomies were identified (2013-2023). Most were minor hepatectomies (194 single-segments, 90 bi-segmentectomies, 14 three-segments, 8 four-segments). Thirty-nine (13%) were for benign histology, while 268 were for cancer (33 hepatocellular carcinoma, 27 biliary, 208 metastatic disease). Patient characteristics were - median age 60 (18-93), 55% male, and median BMI 26 (14-63). Thirty (10%) had cirrhosis. One-hundred-eighty-seven (61%) had previous abdominal surgery. Median operative time was 163 minutes (30-433), with a median blood loss of 50 cc (10-900). There were no deaths and six complications (2%): 2 wound infections, 1 failure to thrive, and 3 perihepatic abscesses. Re-admission was required in 5 patients (1.6%). Of the 268 malignancy cases, 25 (9%) were R1 resections. Of the 128 with superior segment resections (segments 7/8/4A/2/1), there were 12 positive margins (9%) and two readmissions for abscess. Conclusions: Outpatient robotic hepatectomies in well-selected cases are safe (0 mortality, 2% complication, 1.6% re-admission), including resections in the superior or posterior portions of the liver that are challenging with non-articulating laparoscopic instruments.

show abstract

Breast cancer liver metastasis: time to resection and criteria

Cited by 2 publications

References 12 publications

A real‐world study of immune checkpoint inhibitors in advanced triple‐negative breast cancer

A real‐world study of immune checkpoint inhibitors in advanced triple‐negative breast cancer

Outpatient and Ambulatory Extended Recovery Robotic Hepatectomy: Multinational Study of 307 Cases

Contact Info

Product

Resources

About